Browse / CJC & IPA BLEND

CJC & IPA BLEND

Growth & Body Research

Injectable CJC/IPA blends: follow the vial; research-community ranges are often 100 mcg-class per peptide per injection 1–2× daily for non-DAC; weekly-scale for DAC literature LIMITED RESEARCH

Overview

What is CJC & IPA BLEND?

CJC-1295 is a tetrasubstituted GHRH analogue. DAC versions extend half-life via albumin binding; non-DAC (“Mod GRF 1-29”) versions are shorter-acting. Catalog SKUs and blends (e.g. CJC + Ipamorelin) may list either.

Key Benefits

GHRH-receptor GH/IGF-1 axis research, DAC vs non-DAC kinetic options, frequent pairing with ipamorelin in pulsatile protocols.

Mechanism of Action

GHRH-receptor activation on somatotrophs increases GH transcription and release. DAC chemistry changes duration, not the core receptor.

Quick Start Guide

Typical Dose CJC/IPA blends: follow the vial; research-community ranges are often 100 mcg-class per peptide per injection
How Often 1–2× daily for non-DAC; weekly-scale for DAC literature
Where to Inject Abdomen or thigh
Injection Timing Evening is commonly discussed for non-DAC pulses
Effects Timeline IGF-1 changes over weeks in papers
Storage Lyophilized refrigerate; reconstituted 2–8°C
Cycle Length 8–12 weeks
Break Between 4 weeks

Molecular Information

Weight: ~3.4 kDa (Mod GRF 1-29 range)
Length: 29 amino acids (GHRH 1–29 analogue)
Type: GHRH analogue (DAC or non-DAC)

Pharmacokinetics

Peak —

Half-life —

Cleared —

Preclinical / literature values. Not a protocol.